Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AZD0284 in Healthy Subjects
NCT02976831Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Psoriasis vulgaris (PV) comparing AZD0284 with Placebo (2 arms). Primary endpoints: Number of adverse events, Supine vital signs and 2 more. Started Dec 2016; status: completed.
02
Drugs
AZD0284
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02976831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976831.